Neumora Therapeutics, Inc. (NMRA)
NASDAQ: NMRA · Real-Time Price · USD
1.560
-0.400 (-20.41%)
At close: Aug 1, 2025, 4:00 PM
1.650
+0.090 (5.77%)
After-hours: Aug 1, 2025, 7:52 PM EDT

Company Description

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States.

The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.

It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer’s disease.

In addition, the company’s preclinical phase product includes NMRA-NMDA and NMRA-M4R for the treatment of Schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson’s disease.

The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021.

Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

Neumora Therapeutics, Inc.
Neumora Therapeutics logo
CountryUnited States
Founded2019
IPO DateSep 15, 2023
IndustryBiotechnology
SectorHealthcare
Employees110
CEOHenry Gosebruch

Contact Details

Address:
490 Arsenal Way, Suite 200
Watertown, Massachusetts 02472
United States
Phone857 760 0900
Websiteneumoratx.com

Stock Details

Ticker SymbolNMRA
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$17.00
CIK Code0001885522
CUSIP Number640979100
ISIN NumberUS6409791000
Employer ID84-4367680
SIC Code2836

Key Executives

NamePosition
Dr. Daljit Singh Aurora Pharm.D.Chief Operationg and Development officer
Dr. Joshua Pinto Ph.D.President
Michael Lee MilliganChief Financial Officer and Principal Accounting Officer
Dr. Rajesh Manchanda Ph.D.Chief Technical Operations Officer
Dr. Nicholas Brandon Ph.D.Chief Scientific Officer
Jason G. Duncan J.D.Chief Legal and Administrative Officer
Helen RubinsteinHead of Investor Relations
Amy SullivanChief Human Resources Officer
Lori HouleChief Quality Officer
Dr. Maryjo Chamberlain-Tharp Ph.D.Chief Business Officer

Latest SEC Filings

DateTypeTitle
May 30, 20258-KCurrent Report
May 16, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
May 16, 20258-KCurrent Report
May 12, 202510-QQuarterly Report
May 12, 20258-KCurrent Report
May 12, 2025SCHEDULE 13G/AFiling
Apr 29, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 29, 2025DEF 14AOther definitive proxy statements
Apr 11, 2025PRE 14AOther preliminary proxy statements
Apr 11, 20258-K/A[Amend] Current report